[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 148
6. Nasir S, Kayikcioglu A, Aydin MA, Tunçbilek G: Coverage of the cranium with latissimus dorsi in the recurrent basal cell carcinoma of Gorlin syndrome: for protection against clinical invasion. J Craniofac Surg; 2006 May;17(3):599-602
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coverage of the cranium with latissimus dorsi in the recurrent basal cell carcinoma of Gorlin syndrome: for protection against clinical invasion.
  • Gorlin's syndrome is a genetic disorder of autosomal dominant inheritance with characterized primarily by five major findings: multiple basal cell carsinoma (BCC), jaw cysts, pits on the palms and soles, ectopic calcification of the falx cerebri and skeletal anomalies.
  • The risk of recurrent BCC with Gorlin's syndrome is higher than non-syndromic BCC.
  • The authors present a 25-year-old man affected by recurrent basal cell carcinoma on the scalp.
  • Muscle tissue transformed in scalp reconstruction imitates the fascia layer in forming an additional layer against the invasion of skin tumors such as recurrent BCC into the cranium.
  • Free flap reconstruction for recurrent scalp BCC can be best therapy model at Gorlin's syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / surgery. Carcinoma, Basal Cell / surgery. Muscle, Skeletal / transplantation. Scalp / surgery. Skin Neoplasms / surgery. Skull / surgery
  • [MeSH-minor] Adult. Clinical Protocols. Fascia / transplantation. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / surgery. Skin Transplantation / methods

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770207.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Lo Muzio L: Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis; 2008;3:32
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid basal cell carcinoma syndrome (Gorlin syndrome).
  • Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a hereditary condition characterized by a wide range of developmental abnormalities and a predisposition to neoplasms.
  • Main clinical manifestations include multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, hyperkeratosis of palms and soles, skeletal abnormalities, intracranial ectopic calcifications, and facial dysmorphism (macrocephaly, cleft lip/palate and severe eye anomalies).
  • Recurrent jaw cysts occur in 90% of patients.
  • Clinical diagnosis relies on specific criteria.
  • Gene mutation analysis confirms the diagnosis.
  • Antenatal diagnosis is feasible by means of ultrasound scans and analysis of DNA extracted from fetal cells (obtained by amniocentesis or chorionic villus sampling).
  • [MeSH-major] Basal Cell Nevus Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:19-23 [14616807.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1236-40 [14725671.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):313-7 [14987156.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62 [15183409.001]
  • [Cites] J Dermatolog Treat. 2004 Apr;15(2):120-1 [15204165.001]
  • [Cites] Clin Exp Dermatol. 2004 Sep;29(5):542-4 [15347344.001]
  • [Cites] Hum Mutat. 2004 Nov;24(5):441 [15459969.001]
  • [Cites] Arch Fr Pediatr. 1968 Nov;25(9):1083-93 [5728392.001]
  • [Cites] Med Hist. 1969 Jul;13(3):294-7 [4893629.001]
  • [Cites] J Neurosurg. 1971 Nov;35(5):577-84 [5000945.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 Jun;7(8):140-8 [4950929.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1976 Jan;84(1):107-12 [1251730.001]
  • [Cites] J Neurosurg. 1979 Jan;50(1):100-2 [758369.001]
  • [Cites] Cancer. 1979 Dec;44(6):2294-305 [509397.001]
  • [Cites] Br J Oral Surg. 1979 Nov;17(2):135-46 [298837.001]
  • [Cites] Hautarzt. 1981 Sep;32(9):455-8 [7275582.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):350-3 [7053833.001]
  • [Cites] J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):815-23 [6950957.001]
  • [Cites] Ann Neurol. 1982 Apr;11(4):372-6 [7103417.001]
  • [Cites] Wien Klin Wochenschr. 1982 Sep 3;94(16):430-4 [7147982.001]
  • [Cites] Med Pediatr Oncol. 1983;11(3):178-9 [6855699.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):231-6 [6703200.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Feb;47(2):210-2 [6707662.001]
  • [Cites] Can Med Assoc J. 1985 May 1;132(9):1037-8 [3986729.001]
  • [Cites] N Engl J Med. 1986 Mar 13;314(11):700-6 [3951494.001]
  • [Cites] J Am Acad Dermatol. 1986 Nov;15(5 Pt 1):1023-30 [3537024.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] J Am Acad Dermatol. 1987 May;16(5 Pt 1):964-70 [3584581.001]
  • [Cites] J Comput Assist Tomogr. 1987 Sep-Oct;11(5):901-4 [3655059.001]
  • [Cites] Br J Plast Surg. 1987 Sep;40(5):528-31 [3676586.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):309-14 [9096762.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(5):519-22 [17139991.001]
  • [Cites] Childs Nerv Syst. 2007 Jan;23(1):133-6 [16977487.001]
  • [Cites] Clin Exp Dermatol. 2007 Mar;32(2):202-3 [16780502.001]
  • [Cites] J Neurosurg. 2006 Oct;105(4 Suppl):315-20 [17328283.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Am J Otolaryngol. 2007 Sep-Oct;28(5):360-2 [17826543.001]
  • [Cites] J Drugs Dermatol. 2007 Sep;6(9):910-4 [17941362.001]
  • [Cites] Hum Genet. 2007 Dec;122(5):459-66 [17703323.001]
  • [Cites] Br J Cancer. 1997;76(2):141-5 [9231911.001]
  • [Cites] Ann Plast Surg. 1997 Oct;39(4):366-73 [9339279.001]
  • [Cites] Am J Med Genet. 1997 Dec 19;73(3):304-7 [9415689.001]
  • [Cites] Curr Opin Pediatr. 1997 Dec;9(6):630-5 [9425597.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):317-22 [9439661.001]
  • [Cites] Laryngoscope. 1998 Feb;108(2):280-3 [9473082.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):187-91 [9592846.001]
  • [Cites] J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S82-5 [9703130.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):291-7 [9931336.001]
  • [Cites] Clin Genet. 1999 Jan;55(1):34-40 [10066029.001]
  • [Cites] J Am Dent Assoc. 1999 May;130(5):669-74 [10332131.001]
  • [Cites] Dermatologica. 1963;126:106-23 [13954184.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):495-502 [15545745.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Ear Nose Throat J. 2004 Oct;83(10):716-8 [15586876.001]
  • [Cites] Ann Hum Genet. 2004 Nov;68(Pt 6):536-45 [15598212.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] Arch Dermatol Res. 2005 Jan;296(7):303-8 [15565302.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):665-8 [15684600.001]
  • [Cites] Am J Med Genet A. 2005 Jan 30;132A(3):324-8 [15690381.001]
  • [Cites] Hum Mutat. 2005 Mar;25(3):322-3 [15712338.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S256-9 [16227103.001]
  • [Cites] Genet Med. 2005 Nov-Dec;7(9):611-9 [16301862.001]
  • [Cites] Prenat Diagn. 2005 Nov;25(11):997-9 [16231297.001]
  • [Cites] J Pathol. 2006 Jan;208(1):17-25 [16294371.001]
  • [Cites] Echocardiography. 2006 Jan;23(1):79-80 [16412193.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Ann Dermatol Venereol. 2006 Feb;133(2):117-23 [16508594.001]
  • [Cites] Tex Heart Inst J. 2006;33(1):88-90 [16572881.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):e16 [16582078.001]
  • [Cites] Tumour Biol. 2006;27(4):175-80 [16675912.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):417-26 [16788928.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6964-71 [16849540.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):877-8 [16898919.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):548-53 [16909134.001]
  • [Cites] J Dent Res. 2006 Sep;85(9):859-63 [16931872.001]
  • [Cites] Dermatol Ther. 2006 Sep-Oct;19(5):306-14 [17014486.001]
  • [Cites] Dermatol Surg. 2002 Mar;28(3):287-90 [11896785.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Am J Med Genet. 2002 Jul 15;110(4):400-3 [12116218.001]
  • [Cites] Mol Genet Metab. 2002 May;76(1):57-61 [12175781.001]
  • [Cites] Hum Mutat. 2002 Sep;20(3):233-4 [12204003.001]
  • [Cites] J Dermatolog Treat. 2002 Sep;13(3):123-7 [12227875.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):569-72 [12459530.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):47-50 [12604725.001]
  • [Cites] Clin Nucl Med. 2002 Dec;27(12):913-4 [12607884.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):451-2 [12655573.001]
  • [Cites] Am J Obstet Gynecol. 2003 Apr;188(4):1093-5 [12712116.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S64-6 [12734479.001]
  • [Cites] Pediatr Neurol. 2003 Mar;28(3):231-4 [12770681.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):390-2 [12756507.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Oct;3(10):575-80 [17019435.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1084-6 [17021131.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S86-9 [17052541.001]
  • [Cites] Am J Med Genet A. 2006 Dec 1;140(23):2625-30 [16906569.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):790-4 [10782799.001]
  • [Cites] Brain Dev. 2000 Jun;22(4):272-4 [10838118.001]
  • [Cites] J Mol Med (Berl). 2000;78(3):140-6 [10868476.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • [Cites] Cutis. 2000 Jul;66(1):35-8 [10916689.001]
  • [Cites] Arch Dermatol Res. 2000 Sep;292(9):475-6 [11000293.001]
  • [Cites] Br Dent J. 2001 Apr 14;190(7):349-50 [11338037.001]
  • [Cites] J Dermatol Sci. 2001 Sep;27(1):21-6 [11457640.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Dec;64(6):727-30 [3480489.001]
  • [Cites] J Oral Pathol. 1988 Jan;17(1):39-42 [3131508.001]
  • [Cites] J Am Dent Assoc. 1988 Jun;116(7):887-9 [3164743.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] Presse Med. 1988 Nov 26;17(42):2247-50 [2974590.001]
  • [Cites] Dentomaxillofac Radiol. 1987;16(2):99-103 [3333752.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Jun;47(6):629-33 [2656943.001]
  • [Cites] J Am Acad Dermatol. 1989 Jul;21(1):144-5 [2745766.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Aug;47(8):870-3 [2664107.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Aug;15(8):868-71 [2754091.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):64-6 [2045256.001]
  • [Cites] Pediatr Radiol. 1991;21(3):234-5 [2047170.001]
  • [Cites] Genet Couns. 1990;1(3-4):273-7 [2098052.001]
  • [Cites] Am J Med Genet. 1991 Aug 1;40(2):206-10 [1910262.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1494-8 [1540957.001]
  • [Cites] Genet Couns. 1991;2(3):157-62 [1801852.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Pediatr Pathol. 1992 Mar-Apr;12(2):255-62 [1570241.001]
  • [Cites] Pediatr Pathol. 1992 May-Jun;12(3):441-7 [1409143.001]
  • [Cites] Cesk Pediatr. 1993 Mar;48(3):129-32 [8495514.001]
  • [Cites] Dermatology. 1993;186(4):311-2 [8513207.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] Am J Hum Genet. 1993 Sep;53(3):760-7 [8352281.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):447-8 [8012356.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):272-81 [8042672.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):282-90 [8042673.001]
  • [Cites] Lancet. 1994 Aug 13;344(8920):477 [7914587.001]
  • [Cites] Bol Asoc Med P R. 1993 Jan-Mar;85(1-3):24-6 [8060441.001]
  • [Cites] Prenat Diagn. 1994 Aug;14(8):725-7 [7991513.001]
  • [Cites] Genomics. 1994 Aug;22(3):505-11 [8001963.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):472-80 [7856756.001]
  • [Cites] Pediatr Dermatol. 1994 Dec;11(4):323-6 [7899182.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Br J Radiol. 1995 Apr;68(808):361-8 [7795971.001]
  • [Cites] Br J Radiol. 1995 Jun;68(810):596-9 [7627481.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] Arch Dermatol. 1996 Jan;132(1):94-5 [8546496.001]
  • [Cites] Neurology. 1996 Feb;46(2):574-6 [8614540.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Br J Ophthalmol. 1996 Apr;80(4):378 [8703894.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):7-8 [8782809.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Histopathology. 1996 Sep;29(3):247-52 [8884353.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] J Neurosurg. 1997 Feb;86(2):286-8 [9010431.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • (PMID = 19032739.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 164
  • [Other-IDs] NLM/ PMC2607262
  •  go-up   go-down


8. Petre FI, Giuglea C, Eugen T, Silviu M, Jecan C, Mircea G, Bucur N: Surgical treatment of a case of recurrent irradiated basal cell carcinoma of the head with a large soft tissue and bone defect. J Med Life; 2009 Jul-Sep;2(3):266-70
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of a case of recurrent irradiated basal cell carcinoma of the head with a large soft tissue and bone defect.
  • More than 2/3 of these malignances are basal cell carcinomas, which, if left untreated might become very invasive, surgical treatment being more difficult in such cases.
  • Recurrent carcinomas combined with radiation injuries represent a serious challenge even for experienced surgeons regarding the size of the defect and anatomical structures involved.
  • In this paper we present a case of a patient with basal cell carcinoma of the parietal region and the reconstructive treatment involving neurosurgery and plastic surgery team approach, using microsurgery techniques.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20112470.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


9. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, Steijlen PM, Vermeulen A, Neumann H, Kelleners-Smeets NW: Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol; 2008 Dec;9(12):1149-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up.
  • BACKGROUND: Basal-cell carcinoma (BCC) is the most common form of skin cancer and its incidence is still rising worldwide.
  • We did a prospective randomised controlled trial to compare the effectiveness of surgical excision with Mohs' micrographic surgery (MMS) for the treatment of primary and recurrent facial BCC.
  • METHODS: Between Oct 5, 1999, and Feb 27, 2002, 408 primary BCCs (pBCCs) and 204 recurrent BCCs (rBCCs) in patients from seven hospitals in the Netherlands were randomly assigned to surgical excision or MMS.
  • The primary outcome was recurrence of carcinoma, diagnosed clinically by visual inspection with histological confirmation.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Health Care Costs. Mohs Surgery / economics. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery


10. Essers BA, Dirksen CD, Nieman FH, Smeets NW, Krekels GA, Prins MH, Neumann HA: Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol; 2006 Feb;142(2):187-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face.
  • OBJECTIVE: To assess the cost-effectiveness of Mohs micrographic surgery (MMS) compared with the surgical excision for both primary and recurrent basal cell carcinoma (BCC).
  • PARTICIPANTS: A total of 408 primary (374 patients) and 204 recurrent (191 patients) cases of facial BCC were included.
  • MAIN OUTCOME MEASURES: The mean total treatment costs of MMS and surgical excision for both primary and recurrent BCC and the incremental cost-effectiveness ratio, calculated as the difference in costs between MMS and surgical excision divided by their difference in effectiveness.
  • RESULTS: Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros).
  • For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros.
  • CONCLUSIONS: At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC.
  • However, because a 5-year period is normally required to determine definite recurrence rates, it is possible that MMS may become a cost-effective treatment for recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Facial Neoplasms / economics. Mohs Surgery / economics
  • [MeSH-minor] Aged. Cost-Benefit Analysis. Female. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Netherlands. Prospective Studies. Quality of Life. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2006 Feb;142(2):231-2 [16490852.001]
  • [CommentIn] Arch Dermatol. 2006 Sep;142(9):1235; author reply 1235-6 [16983019.001]
  • (PMID = 16490846.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Beer K, Waibel J: Recurrent basal cell carcinoma discovered using positron emission tomography (PET) scanning. J Drugs Dermatol; 2008 Sep;7(9):879-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basal cell carcinoma discovered using positron emission tomography (PET) scanning.
  • A lesion detected on a positron emission tomography/computerized tomography (PET/CT) scan localized to the skin and was determined to be a large, recurrent basal cell carcinoma.
  • This case demonstrates the ability of PET scans to detect recurrent, nonmelanoma skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Positron-Emission Tomography / methods. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112803.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Griffiths RW, Suvarna SK, Stone J: Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg; 2005 Sep;58(6):795-805
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do basal cell carcinomas recur after complete conventional surgical excision?
  • For 1378 patients treated in the 11 years 1988-1998 by conventional excision of 1635 basal cell carcinomas, 1516 first index lesions were histologically completely excised.
  • Measured clearance margins around the initial lesions at or near sites of presumptive recurrent lesions were noted and the lesions recorded photographically.
  • These figures indicate there is a low order of probability for the incidence of recurrent basal cell carcinoma during minimum 5 years follow period after conventional surgical excision and conventional histological assessment of tumour resection margins.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2007;60(4):451-3 [17349608.001]
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2006;59(11):1247 [17046636.001]
  • (PMID = 16086990.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Ong LY, Lane CM: Eyelid contracture may indicate recurrent basal cell carcinoma, even after Mohs' micrographic surgery. Orbit; 2009;28(1):29-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid contracture may indicate recurrent basal cell carcinoma, even after Mohs' micrographic surgery.
  • Mohs' micrographic surgery (MMS) is an effective means of margin control in the management of periocular basal cell carcinomas (BCC).
  • We describe three cases of recurrent BCC that presented with progressive eyelid contracture after MMS.
  • Careful long-term surveillance with serial photography may identify early eyelid contracture and thus assist in the detection of recurrent BCC after MMS and improve patient outcome.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Contracture / pathology. Eyelid Neoplasms / surgery. Mohs Surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19229742.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


1
Advertisement
4. Galimberti G, Pontón Montaño A, Ferrario D, Kowalczuk A, Galimberti R: [Mohs micrographic surgery for the treatment of basal cell carcinoma]. Actas Dermosifiliogr; 2010 Dec;101(10):853-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mohs micrographic surgery for the treatment of basal cell carcinoma].
  • [Transliterated title] Cirugía micrográfica de Mohs en el tratamiento de carcinoma basocelular.
  • INTRODUCTION: Basal cell carcinoma accounts for 75% of all nonmelanoma skin cancer.
  • Here, we evaluate the efficacy of Mohs micrographic surgery for the treatment of basal cell carcinoma.
  • MATERIAL AND METHODS: A retrospective review of cases of basal cell carcinoma treated with Mohs micrographic surgery between October 2003 and June 2009 was performed using patient records from Hospital Italiano in Buenos Aires, Argentina.
  • RESULTS: A total of 2412 basal cell carcinomas treated with Mohs micrographic surgery were identified; 50.5% were in women and 49.5% in men.
  • Ten percent of the tumors were recurrent following previous treatment.
  • CONCLUSIONS: In our experience, Mohs micrographic surgery is effective for the treatment of high-risk basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159261.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


15. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • METHODS: OTR who developed recurrent skin cancers, SCC, and/or basal cell carcinoma (BCC), were given low-dose capecitabine 1g/m2 divided in two daily doses, day 1-14 of 21-day treatment cycle.
  • CONCLUSIONS: Oral capecitabine significantly decreases the incidence rates of recurrent SCC in OTR and has manageable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Wadhera A, Fazio M, Bricca G, Stanton O: Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J; 2006;12(5):7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data?
  • A 55-year-old man presented to Skin Cancer Surgery Center of Sacramento in 1995 for Mohs micrographic surgery of a 1.5-cm nodular basal cell carcinoma located on the right superior antihelix and scaphoid fossa.
  • A recurrent basal cell carcinoma developed at the same site 5 years later and was treated also by Mohs micrographic surgery.
  • One year later (approximately 6 years after the diagnosis of the initial basal cell carcinoma), a right parotid mass was noted on routine physical exam.
  • CT scan and fine needle aspiration of the mass revealed metastatic basal cell carcinoma.
  • He has done well for the past 2 years since the diagnosis of his metastatic lesion.
  • Basal cell carcinoma is the most common malignancy in the world.
  • We report a case of basal cell carcinoma metastatic to the parotid gland and critically review the incidence data reported in the literature.
  • We recommended the collection of more current and accurate incidence data for basal cell carcinoma and metastatic basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Ear Neoplasms / pathology. Parotid Neoplasms / secondary
  • [MeSH-minor] Humans. Incidence. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962022.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


18. Farhadi M, Kamrava SK, Behzadi AH, Rafiezadeh P, Asghari A, Rezvan F, Maleki S: The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma. J Drugs Dermatol; 2010 Feb;9(2):122-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma.
  • OBJECTIVES: A number of investigations have already been carried out to assess the effect of photodynamic therapy (PDT) on primary basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions, but lack of investigations on recurrent lesions or lesions with treatment failure, prompted the authors to carry out this study.
  • The aim of the present study was to evaluate the efficacy of photodynamic therapy on recurrent BCC and SCC lesions on head and neck skin.
  • PATIENTS AND METHODS: A total of 30 patients, including 16 men and 14 women, were selected from patients with recurrent SCC and BCC who referred to Iran university ENT research center Rasool-e-Akram Hospital, Tehran-Iran, met the criteria and entered the study.
  • The final result of complete response rate in three years of follow up, demonstrated that 16 (64%) patients out of 25 were disease-free from recurrent BCC and SCC (Table 1).
  • DISCUSSION: The obtained data from the current study is supportive of the recommended treatment method of PDT as an effective, tolerable and less invasive treatment in patients with recurrent BCC and SCC carcinomas, particularly when cosmetic effects are an important consideration.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy


19. Leibovitch I, McNab A, Sullivan T, Davis G, Selva D: Orbital invasion by periocular basal cell carcinoma. Ophthalmology; 2005 Apr;112(4):717-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital invasion by periocular basal cell carcinoma.
  • OBJECTIVES: To present a large series of patients with orbital invasion by periocular basal cell carcinoma (BCC).
  • Most tumors (84.4%) were recurrent or previously incompletely excised, and the medial canthus was most frequently involved (56.2%).
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Peripheral Nervous System Neoplasms / radiotherapy. Peripheral Nervous System Neoplasms / secondary. Peripheral Nervous System Neoplasms / surgery. Radiotherapy. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808267.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


20. Salvini C, Massi D, Cappugi P: Recurrent basal cell carcinoma of the nose successfully treated by photodynamic therapy. J Eur Acad Dermatol Venereol; 2009 Jan;23(1):73-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basal cell carcinoma of the nose successfully treated by photodynamic therapy.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Nose / pathology. Photochemotherapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462294.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


21. Kimball KJ, Straughn JM, Conner MG, Kirby TO: Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol; 2006 Aug;102(2):400-2
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basosquamous cell carcinoma of the vulva.
  • BACKGROUND: Basosquamous cell carcinoma (BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
  • CASE: A case of recurrent BSC of the vulva treated with unilateral radical vulvectomy and unilateral lymph node dissection is reported.
  • CONCLUSION: BSC is a rare disorder of the vulva.
  • The metastatic potential of this tumor is not fully understood, but likely is intermediate between squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624392.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Rodriguez C, Barriuso V, Chan LS: Extensive basal cell carcinoma with probable bone metastasis. Cutis; 2007 Jul;80(1):60-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive basal cell carcinoma with probable bone metastasis.
  • Metastasis of basal cell carcinoma (BCC) rarely occurs.
  • Few cases have been reported in the literature; those cases reported generally resulted from chronic, extensive, recurrent lesions on the head or neck.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725067.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


23. Cohen PR, Schulze KE, Nelson BR: Basal cell carcinoma with mixed histology: a possible pathogenesis for recurrent skin cancer. Dermatol Surg; 2006 Apr;32(4):542-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with mixed histology: a possible pathogenesis for recurrent skin cancer.
  • BACKGROUND: Basal cell carcinoma with mixed histology (BCC-MH) demonstrates more than one pathologic pattern of tumor.
  • Appropriate therapy for the nonaggressive tumor subtype diagnosed from a superficial biopsy may not be adequate to treat the unsuspected aggressive tumor subtype, resulting in recurrent skin cancer.
  • CONCLUSION: More than 40% of basal cell carcinomas referred for removal of the residual tumor were BCC-MH.
  • Subsequently, the cancer may recur if the initial treatment for the diagnosed nonaggressive tumor subtype is inadequate for the undiscovered aggressive carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681663.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


24. Kleydman Y, Manolidis S, Ratner D: Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol; 2009 Jun;60(6):1045-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with intracranial invasion.
  • The risk of invasion and destruction of cranium, underlying dura, and cranial nerves by basal cell carcinoma (BCC) is extremely low, with an estimated incidence of 0.03%.
  • We describe a case of intracranial invasion of a multiply recurrent nasal BCC, which caused progressive bilateral blindness from optic nerve compression, with spinal canal involvement causing subsequent lower extremity weakness and paralysis.
  • This case underscores the importance of early and appropriate treatment of high risk BCC, and aggressive treatment of recurrent lesions as early as possible.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Orbit / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Blindness / etiology. Female. Humans. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467376.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Freier K, Flechtenmacher C, Devens F, Hartschuh W, Hofele C, Lichter P, Joos S: Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep; 2006 May;15(5):1141-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma.
  • Formation of basal cell carcinoma (BCC) has been linked to deregulation in the sonic hedgehogh (Shh) signalling pathway.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Dosage. Genes, myc / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596176.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


26. Leyngold M, Leyngold I, Letourneau PR, Zamboni WA, Shah H: Basal cell carcinoma and rhinophyma. Ann Plast Surg; 2008 Oct;61(4):410-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma and rhinophyma.
  • Basal cell carcinoma (BCC) is a rare finding in patients with rhinophyma.
  • The patient suffered from chronic drainage and recurrent infections that failed conservative treatment with oral and topical antibiotics.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Deformities, Acquired / surgery. Nose Neoplasms / surgery. Precancerous Conditions / surgery. Rhinophyma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Humans. Male. Nose / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812712.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Caresana G, Giardini R: Dermoscopy-guided surgery in basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Dec;24(12):1395-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy-guided surgery in basal cell carcinoma.
  • BACKGROUND: In basal cell carcinoma (BCC), excision margins between 3 and 10 mm, according to site, size, borders, previous treatment and histology, can allow for radical excision in at least 95% of cases.
  • Morpheaform BCC, deeply recurrent BCC, BCC in Gorlin-Goltz syndrome, BCC located in sites not accessible through dermoscopy and superficial multifocal BCC were excluded.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Dermoscopy. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20384678.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Naumann IC, Cordes SR: Giant basal cell carcinoma of the forehead with extensive intracranial involvement. Ann Otol Rhinol Laryngol; 2007 Sep;116(9):663-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the forehead with extensive intracranial involvement.
  • Basal cell carcinoma (BCC) is the most common malignant skin lesion and is frequently curatively treated with local excision.
  • We describe a case of a recurrent BCC that aggressively grew from the forehead skin through the skull and into the frontal lobe.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Forehead. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926588.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Paavilainen V, Aaltonen M, Tuominen J, Saari KM: Histological characteristics of basal cell carcinoma of the eyelid. Ophthalmic Res; 2007;39(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological characteristics of basal cell carcinoma of the eyelid.
  • PURPOSE: To evaluate the histological subtypes of basal cell carcinoma (BCC) of the eyelid and to determine their effect on the size, depth of invasion and need of retreatment of a nonselected patient material seen in south-western Finland.
  • CONCLUSIONS: The nodular subtype of BCC should be regarded as a potentially invasive and recurrent tumor.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164577.001).
  • [ISSN] 0030-3747
  • [Journal-full-title] Ophthalmic research
  • [ISO-abbreviation] Ophthalmic Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


30. Chai L, Tang J: [Analysis of 41 cases of basal cell carcinoma in maxillofacial area]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr;20(7):297-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of basal cell carcinoma in maxillofacial area].
  • OBJECTIVE: To explore the incidence, location and relationship between surgical margin and metastasis of basal cell carcinoma (BCC) in maxillofacial area.
  • Of all the 41 patients, 4 patients were found to suffer regional lymph nodes metastasis or local bone destruction at the first visit (9.8%), 3 patients (7.3%) had a recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell. Facial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780141.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, Gupta G, Scottish Dermatological Society: Management of basal cell carcinoma by surveyed dermatologists in Scotland. Clin Exp Dermatol; 2006 Sep;31(5):648-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of basal cell carcinoma by surveyed dermatologists in Scotland.
  • BACKGROUND: The British Association of Dermatologists (BAD) has produced guidelines for management of basal cell carcinoma (BCC) in the UK.
  • A diagnostic biopsy was taken in 22% of lesions, and the rest were treated definitively after a clinical diagnosis of BCC, of which 90% were confirmed on histology.
  • Four of 21 recurrent tumours and 9 of 81 tumours on high-risk areas of the face were managed with curettage and cautery or cryotherapy, rather than surgical excision.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901303.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


32. Griffin JR, Cohen PR, Tschen JA, Mullans EA, Schulze KE, Martinelli PT, Nelson BR: Basal cell carcinoma in childhood: case report and literature review. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S97-102
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in childhood: case report and literature review.
  • Childhood onset basal cell carcinoma is uncommon.
  • In addition to occurring in children with albinism, Bazex syndrome, basal cell carcinoma nevus syndrome, nevus sebaceus, radiotherapy-treated cancers, solid organ transplants, and xeroderma pigmentosum, childhood onset basal cell carcinoma has also occurred, albeit less commonly, de novo.
  • We describe a boy with idiopathic childhood onset basal cell carcinoma.
  • Previously published children with de novo basal cell carcinoma were collected from computerized medical literature search (PubMed) and citations from earlier reports.
  • To our knowledge, childhood onset idiopathic basal cell carcinoma has been observed in a total of 107 children, including our patient.
  • Basal cell carcinoma in children may be associated with prior sun exposure.
  • However, 15 of 85 children, nearly 20%, developed recurrent tumors during a follow-up period ranging from 4 months to 20 years.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938034.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


33. Simeonov R, Simeonova G: Comparative morphometric analysis of recurrent and nonrecurrent canine basal cell carcinomas: a preliminary report. Vet Clin Pathol; 2010 Mar;39(1):96-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative morphometric analysis of recurrent and nonrecurrent canine basal cell carcinomas: a preliminary report.
  • BACKGROUND: Most reports of canine basal cell carcinomas (BCCs) focus on morphologic appearance rather than biologic behavior.
  • The dogs were monitored by their owners over a period of 60 weeks to detect local recurrence of the tumor; recurrent tumors were confirmed histologically.
  • RESULTS: Six nonrecurrent and 5 recurrent tumors were analyzed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2010 Jun;39(2):133; author reply 133-4 [20624263.001]
  • (PMID = 19645743.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ting PT, Kasper R, Arlette JP: Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg; 2005 Jan;9(1):10-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: report of two cases and literature review.
  • BACKGROUND: Metastatic basal cell carcinoma (MBCC) is defined as primary cutaneous basal cell carcinoma (BCC) that spreads to distant sites as histologically similar metastatic deposits of BCC.
  • Patients with MBCC often begin with long-standing primary BCC lesions that are either large or recurrent after treatment.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Facial Neoplasms / pathology. Facial Neoplasms / therapy
  • [MeSH-minor] Fatal Outcome. Female. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Metastasis. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208438.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


35. Khandwala MA, Lalchan SA, Chang BY, Habib M, Chakrabarty A, Cassells-Brown A: Outcome of periocular basal cell carcinoma managed by overnight paraffin section. Orbit; 2005 Dec;24(4):243-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of periocular basal cell carcinoma managed by overnight paraffin section.
  • RESULTS: This study yielded 93 basal cell carcinomas (BCCs) of which 86 were of primary origin and 7 were recurrent tumours.
  • Among recurrent BCCs, there was one recurrence (12.5%) and this was despite histological clearance having been reported.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Paraffin Embedding / methods
  • [MeSH-minor] Aged. Female. Humans. Male. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354633.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Simeonov R, Simeonova G: Nucleomorphometric analysis of feline basal cell carcinomas. Res Vet Sci; 2008 Jun;84(3):440-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleomorphometric analysis of feline basal cell carcinomas.
  • Twenty-four feline spontaneous basal cell carcinomas (BCCs) were analyzed by computerized nuclear morphometry.
  • The study included 15 non-recurrent and 9 recurrent tumours.
  • The analysis of data of the non-recurrent BCCs and the recurrent tumours revealed statistically significant differences between those groups (p<0.001) as well as between infiltrative and clear types of BCCs (p<0.05).
  • The results indicate that nuclear morphometry is able to predict recurrent tumour growth and helps to differentiate histological subtypes of BCCs in cats.
  • [MeSH-major] Carcinoma, Basal Cell / veterinary. Cat Diseases / pathology. Cell Nucleus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706734.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Swanson EL, Amdur RJ, Mendenhall WM, Morris CG, Kirwan JM, Flowers F: Radiotherapy for basal cell carcinoma of the medial canthus region. Laryngoscope; 2009 Dec;119(12):2366-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for basal cell carcinoma of the medial canthus region.
  • OBJECTIVES/HYPOTHESIS: To report outcome for patients treated with radiotherapy (RT) for basal cell carcinoma of the medial canthus.
  • METHODS: Thirty-three patients treated with RT at the University of Florida between 1965 and 2005 for basal cell carcinoma of the medial canthus were retrospectively reviewed.
  • In patients treated with RT alone, the local control rate was 94% with de novo lesions and 67% if the lesion was recurrent after prior surgery.
  • Patients with recurrent tumors and gross disease at the time of RT have a suboptimal cure rate.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Eyelid Neoplasms / radiotherapy
  • [MeSH-minor] Dose-Response Relationship, Radiation. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780029.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G: Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol; 2009 Aug;36(8):878-81
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
  • An 84-year-old male presented with recurrent nodular infiltrative basal cell carcinoma on the left shoulder.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy. Vitiligo / chemically induced. Vitiligo / pathology

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586497.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


39. Lear W, Mittmann N, Barnes E, Breen D, Murray C: Cost comparisons of managing complex facial basal cell carcinoma: Canadian study. J Cutan Med Surg; 2008 Mar-Apr;12(2):82-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost comparisons of managing complex facial basal cell carcinoma: Canadian study.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignancy and accounts for over 60,000 new cases of cancer in Canada annually.
  • All were located on the head and neck and were either recurrent disease or located in "at risk" sites such as the eye, ear, lip, or nose.
  • Although we did notice a trend toward greater costs in patients with recurrent disease, in males, younger patients, and tumors present for > 1 year, these did not reach significance within our sample size.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Cost of Illness. Facial Neoplasms / economics. Mohs Surgery / economics. Skin Neoplasms / economics
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / economics. Ontario. Radiotherapy / economics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346405.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Essers B, Nieman F, Prins M, Smeets N, Neumann H: Perceptions of facial aesthetics in surgical patients with basal cell carcinoma. J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1209-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perceptions of facial aesthetics in surgical patients with basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is a non-melanoma form of skin cancer that is frequently localized within the cervicofacial area.
  • (ii) if there was a significant difference between primary and recurrent BCC patients; and (iii) between patients who had Mohs micrographic surgery (MMS) or surgical excision (SE).
  • There was no statistically significant difference on facial aesthetics between the group with a primary or recurrent BCC and patients treated with MMS or SE.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Esthetics. Face. Skin Neoplasms / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894707.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  •  go-up   go-down


41. Madge SN, Khine AA, Thaller VT, Davis G, Malhotra R, McNab A, O'Donnell B, Selva D: Globe-sparing surgery for medial canthal Basal cell carcinoma with anterior orbital invasion. Ophthalmology; 2010 Nov;117(11):2222-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Globe-sparing surgery for medial canthal Basal cell carcinoma with anterior orbital invasion.
  • PURPOSE: To describe a case series of patients with anterior orbital invasion by medial canthal basal cell carcinoma (BCC) managed with non-exenterating surgery.
  • Twelve of 20 patients (60%) had recurrent BCCs, with 1 patient having had prior radiotherapy for previously incomplete excision.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Neoplasm Recurrence, Local. Ophthalmologic Surgical Procedures. Orbit / surgery. Orbital Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20570356.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Su SY, Giorlando F, Ek EW, Dieu T: Incomplete excision of basal cell carcinoma: a prospective trial. Plast Reconstr Surg; 2007 Oct;120(5):1240-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma: a prospective trial.
  • Reported rates of incomplete excision of basal cell carcinoma vary widely (5 to 25 percent) among centers worldwide.
  • METHODS: From January of 2001 to December of 2002, 1214 basal cell carcinomas were excised at Peter MacCallum Cancer Centre.
  • Risk factors for incomplete excision are the head site; morpheic, superficial, and infiltrative subtypes; lesions larger than 20 mm in diameter; the presence of multiple lesions; repair by skin graft; and recurrent and previously incompletely excised basal cell carcinomas.
  • CONCLUSIONS: This is the largest prospective study of incomplete excision of basal cell carcinomas.
  • Preoperative "red-flagging" of basal cell carcinomas most at risk of incomplete excision may lead to a better result.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898596.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Bøgelund FS, Philipsen PA, Gniadecki R: Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol; 2007;87(4):330-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the recurrence rate of basal cell carcinoma.
  • The aim of this retrospective survey was to determine recurrence rates after treatment of basal cell carcinomas in a single academic dermatology department.
  • A total of 1016 patients with 1593 histologically verified basal cell carcinomas (n=1212 primary and n=381 relapsing) were included.
  • The relapse rate for primary basal cell carcinomas on the scalp was highest (odds ratio (OR)=2.8, 95% confidence interval (CI) 1.5-5.3).
  • T2 and T3 tumours showed a 2- and 3-fold increased relapse rate, respectively, compared with T1 basal cell carcinomas.
  • Recurrent basal cell carcinomas had a higher relapse rate than primary lesions (OR=1.8, CI=1.4-2.2).
  • Thus, in an uncontrolled, real-life situation curettage or photodynamic therapy are associated with significantly higher relapse risk than excision and radiotherapy and therefore should not be used for high risk primary tumours or recurrent tumours.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598036.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


44. Kaplan AL, Weitzul SB, Taylor RS: Longitudinal diminution of tumor size for basal cell carcinoma suggests shifting referral patterns for Mohs surgery. Dermatol Surg; 2008 Jan;34(1):15-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal diminution of tumor size for basal cell carcinoma suggests shifting referral patterns for Mohs surgery.
  • OBJECTIVE: The objective was to examine whether referral patterns for basal cell carcinoma (BCC) at an academic Mohs surgery practice have shifted over recent years toward referral for smaller, lower risk tumors.
  • Statistical analyses were used to identify differences in tumor size, distribution by anatomic site, and primary versus recurrent status.
  • Tumors were twice as likely to be recurrent in 1996 (15.1%) than in 2004 (7.4%).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mohs Surgery. Referral and Consultation / trends. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Longitudinal Studies. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053056.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion. J Am Acad Dermatol; 2005 Sep;53(3):458-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion.
  • BACKGROUND: Perineural invasion (PNI) is an important factor may possibly influence the aggressiveness of basal cell carcinoma (BCC).
  • Most cases occurred in male patients (61%; P = .006) and in previously recurrent tumors (60.4%; P < .001).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Peripheral Nerves / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112353.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


51. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer; 2009;9:262
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.
  • BACKGROUND: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery.
  • The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).
  • METHODS: Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks.
  • CONCLUSION: The peri- and intralesional combination of IFNs-alpha and -gamma was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Interferons / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bayes Theorem. Drug Resistance, Neoplasm. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Prospective Studies. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2357-60 [10875919.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40 [11271459.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):933-7 [12072058.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jun;22(6):719-28 [12162884.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1485-95 [12368221.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):116-20 [14692941.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1105-11 [2108862.001]
  • [Cites] Int Ophthalmol. 1990 Jul;14(4):285-94 [2370130.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(5):321-4 [2115817.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1637-49 [2120392.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9 [1869642.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ann Ophthalmol. 1993 Jan;25(1):11-3 [8427483.001]
  • [Cites] Drug Saf. 1994 Feb;10(2):115-50 [7516663.001]
  • [Cites] J Am Acad Dermatol. 1994 Nov;31(5 Pt 2):916-20 [7962748.001]
  • [Cites] Drugs. 1995 Jul;50(1):48-61 [7588089.001]
  • [Cites] Chin Med Sci J. 2007 Mar;22(1):38-43 [17441316.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1974-8 [17513803.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):889-92 [17638733.001]
  • [Cites] J Immunother. 2008 Jan;31(1):28-33 [18157009.001]
  • [Cites] Acta Pol Pharm. 2008 May-Jun;65(3):345-51 [18646554.001]
  • [Cites] J Immunother. 2008 Sep;31(7):599-606 [18600184.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):205-13 [18849299.001]
  • [Cites] Br J Nurs. 2009 Mar 26-Apr 8;18(6):346, 348-50 [19329898.001]
  • [Cites] Cancer Detect Prev. 1997;21(2):191-5 [9101080.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Dermatol Clin. 1998 Apr;16(2):377-98 [9589211.001]
  • [Cites] Acta Oncol. 1999;38(5):613-7 [10427950.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1849-57 [15547726.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):300-4 [15619125.001]
  • [Cites] Ophthalmology. 2005 Apr;112(4):717-23 [15808267.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2937-46 [15837745.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):217-22 [10605014.001]
  • (PMID = 19643007.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9008-11-1 / Interferons
  • [Other-IDs] NLM/ PMC2724551
  •  go-up   go-down


52. Mc Loone NM, Tolland J, Walsh M, Dolan OM: Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol; 2006 Jul;20(6):698-701
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of basal cell carcinomas: an audit of current practice.
  • BACKGROUND: Follow-up of patients after treatment of basal cell carcinoma (BCC) allows for monitoring of recurrence and detection of new tumours, but adds a significant burden to outpatient clinics.
  • Medical charts were reviewed to determine data recorded about lesions, the number of recurrent BCCs and new tumours detected, and the number of patients completing follow-up.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Guideline Adherence. Practice Guidelines as Topic. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Male. Medical Audit. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / epidemiology. Practice Patterns, Physicians' / statistics & numerical data. Prognosis. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836498.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Chu CY, Cha ST, Chang CC, Hsiao CH, Tan CT, Lu YC, Jee SH, Kuo ML: Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells. Oncogene; 2007 Apr 12;26(17):2491-501
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells.
  • Basal cell carcinoma (BCC) is one of the most common skin neoplasms in humans and is usually characterized by local aggressiveness with little metastatic potential, although deep invasion, recurrence, and regional and distant metastases may occur.
  • We found that human BCC tissues and a BCC cell line had significant expression of CXCR4, which was higher in invasive than non-invasive BCC types.
  • Further, of 19 recurrent tumors among 390 BCCs diagnosed during the past 12 years, 17/19 (89.5%) had high CXCR4 expression.
  • We found that the CXCR4 ligand, stromal-cell-derived factor 1alpha (SDF-1alpha), directed BCC invasion and that this was mediated by time-dependent upregulation of mRNA expression and gelatinase activity of matrix metalloproteinase-13 (MMP-13).
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. Carcinoma, Basal Cell / pathology. Chemokines, CXC / physiology. Matrix Metalloproteinase 13 / physiology
  • [MeSH-minor] Cell Line, Tumor. Chemokine CXCL12. Humans. Neoplasm Invasiveness. Receptors, CXCR4 / biosynthesis. Receptors, CXCR4 / genetics


54. Soysal HG, Soysal E, Markoç F, Ardiç F: Basal cell carcinoma of the eyelids and periorbital region in a Turkish population. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):201-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids and periorbital region in a Turkish population.
  • PURPOSE: To review the clinical and histopathologic features, treatment, and outcomes of eyelid basal cell carcinomas.
  • METHODS: The clinical records and histopathologic specimens of 311 patients with eyelid basal cell carcinomas were reviewed and analyzed retrospectively.
  • The most common histologic subtypes were infiltrative, nodular, and basosquamous basal cell carcinomas.
  • Nearly one-third (29.9%) of the patients were previously recurrent.
  • Recurrent basal cell carcinomas were larger, with longer duration of lesion and a higher rate of orbital and perineural invasion.
  • Basosquamous basal cell carcinomas were more likely to have prior recurrences, larger lesion size, and the highest rate of orbital invasion.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520835.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Kobayashi T, Maruyama S, Cheng J, Ida-Yonemochi H, Yagi M, Takagi R, Saku T: Histopathological varieties of oral carcinoma in situ: Diagnosis aided by immunohistochemistry dealing with the second basal cell layer as the proliferating center of oral mucosal epithelia. Pathol Int; 2010 Mar;60(3):156-66
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological varieties of oral carcinoma in situ: Diagnosis aided by immunohistochemistry dealing with the second basal cell layer as the proliferating center of oral mucosal epithelia.
  • To make reproducible diagnoses for oral carcinoma in situ (CIS), combined immunohistochemistry directed at the positioning of squamous cell proliferation (Ki-67) and differentiation (keratin (K) 13 and K19) was used, both of which support histological evaluations by providing biological evidence.
  • Normal/hyperplastic epithelia was defined by K19+ cells only in the first basal layer, K13+ cells in the third basal and upper layers, and sporadic Ki-67+ cells in the second basal layer.
  • These profiles indicated that a proliferating center of the oral epithelium is located in the parabasal cell layer, and K19 and K13 can be regarded as markers for basal and prickle cells, respectively.
  • When the definition was applied, surgical margins in 172 recurrent cases were shown to contain CIS (39.4%) and squamous cell carcinoma (55.8%), indicating that the new diagnostic criteria for CIS reflected clinical behaviors of the cases.
  • [MeSH-major] Carcinoma in Situ / metabolism. Cell Proliferation. Mouth Mucosa / metabolism. Mouth Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403041.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


56. Tawfik HA, Assem M, Elkafrawy MH, Talib NM: Scar sarcoidosis developing 16 years after complete excision of an eyelid Basal carcinoma. Orbit; 2008;27(6):438-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scar sarcoidosis developing 16 years after complete excision of an eyelid Basal carcinoma.
  • A 56-year-old patient developed sarcoidosis on top of an old eyelid scar from previous removal of an eyelid basal cell carcinoma 16 years prior to presentation.
  • Sarcoidosis should be considered in the differential diagnosis of recurrent eyelid skin cancers especially if the external appearance or the duration after the initial surgery does not fit the criteria for recurrence.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Postoperative Complications. Sarcoidosis / etiology
  • [MeSH-minor] Cicatrix / diagnosis. Cicatrix / etiology. Diagnosis, Differential. Female. Humans. Middle Aged. Ophthalmologic Surgical Procedures

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19085299.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Nemet AY, Deckel Y, Martin PA, Kourt G, Chilov M, Sharma V, Benger R: Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol; 2006 Aug;142(2):293-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of periocular basal and squamous cell carcinoma: a series of 485 cases.
  • PURPOSE: To analyze the outcome of management of patients with basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) in a tertiary referral eye center in Sydney, Australia.
  • Twenty-seven patients (5.6%) had a recurrent tumor.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Eyelid Neoplasms / surgery. Neoplasm Recurrence, Local. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876511.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Rudolph J, Berl J, Hamm B, Klingebiel R: Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy. Acta Radiol; 2006 Mar;47(2):205-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy.
  • Myotonic dystrophy Curschmann Steinert is a common hereditary disorder that in some cases can be combined with cutaneous tumors, which is an association that is rarely described in the literature.
  • We present the magnetic resonance imaging in the unusual combination of a patient with known myotonic dystrophy and recurrent basal cell tumor.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Basal Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Magnetic Resonance Imaging. Myotonic Dystrophy / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604969.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


59. Villalon-Lopez JS, Valle-Mejia CA, Patino-Lara A, Moreno-Perez BA, Munoz-Lopez JA, Alcantar-Andrade A: Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review. J Cancer Res Ther; 2006 Jul-Sep;2(3):140-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review.
  • Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation as an important risk factor for development of illness such as severe solar burns during childhood or adolescence.
  • Orbital exenteration is also used for treatment of malignancies of ocular tissues, mainly squamous cell carcinoma, sebaceous cell carcinoma and BCC.
  • The case of a 77-year-old patient is presented with BCC of inferior eyelid of 14 years' duration, formerly managed with radiotherapy; however, due to recurrent illness and invasion to the maxillary antrum, he needed supraestructure maxillectomy with left orbital exenteration.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Maxilla / surgery. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998694.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


60. Sebastián Villalón-López J, Arturo Valle-Mejía C, Patiño-Lara A, Moreno-Pérez Bertha A, Alejo Muñoz-López J, Alcantar-Andrade A: Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review. J Cancer Res Ther; 2005 Jul-Sep;1(3):132-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review.
  • Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation (UVR) as important risk factor for development of the illness as such as severe solar burns during childhood or adolescence.
  • Orbital exenteration is also used for treatment of malignancies of ocular tissues, mainly squamous cell carcinoma, sebaceous cell carcinoma and BCC.
  • The case of a 77 year-old patient is presented with BCC of inferior eyelid of 14 years duration, formerly managed with radiotherapy and, due to recurrent illness and invasion to the maxillary antrum; he needed supraestructure maxillectomy with left orbital exenteration.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Maxilla / surgery. Orbit Evisceration / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998643.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 15
  •  go-up   go-down


61. Wetzig T, Woitek M, Eichhorn K, Simon JC, Paasch U: Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up. Dermatology; 2010;220(4):363-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up.
  • BACKGROUND: The incidence of skin cancer and especially basal cell carcinoma (BCC) has increased in the last few decades.
  • METHODS: A retrospective analysis of 671 patients (45.3% male, 54.7% female) with 777 primary and 85 with recurrent BCC were collected during 2001-2003.
  • In the group with primary BCC (n = 562), 3 tumor recurrences (0.5%) were identified; in the group with recurrent BCC (n = 68), 2 tumor recurrences (2.9%) were seen, resulting in an overall 5-year recurrence rate of 0.8% for all patients with BCC.
  • CONCLUSION: Local complete tumor resection confirmed by complete margin control using paraffin-embedded sections can achieve excellent cure rates for both primary and recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Microsurgery / methods. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20484877.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


62. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol; 2005 Sep;53(3):452-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up.
  • BACKGROUND: Long-term follow-up is essential to evaluate the role of Mohs micrographic surgery (MMS) in the treatment for cutaneous basal cell carcinoma (BCC).
  • Fifty-six percent of the tumors were primary and 44% were previously recurrent.
  • Recurrence at 5 years was diagnosed in 1.4% of primary and in 4% of recurrent tumors.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery


63. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years. J Am Acad Dermatol; 2005 Sep;53(3):445-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years.
  • BACKGROUND: Only a few prospective studies have been published on surgical treatments for cutaneous basal cell carcinoma (BCC).
  • In 43.8% of cases BCC was a recurrent tumor.
  • Previously recurrent tumors were larger than primary tumors (P < .001), had a larger postexcision defect and more subclinical extension, and required more levels of excision (P < .001).
  • That previously recurrent tumors were larger and demonstrated a more extensive subclinical extension compared with primary tumors emphasizes the importance of initial tumor eradication with margin control.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Maxillary Neoplasms / surgery. Mohs Surgery. Neoplasm Recurrence, Local / surgery. Nose Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Australia. Cheek. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prospective Studies

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112351.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


64. Morris DS, Elzaridi E, Clarke L, Dickinson AJ, Lawrence CM: Periocular basal cell carcinoma: 5-year outcome following Slow Mohs surgery with formalin-fixed paraffin-embedded sections and delayed closure. Br J Ophthalmol; 2009 Apr;93(4):474-6
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periocular basal cell carcinoma: 5-year outcome following Slow Mohs surgery with formalin-fixed paraffin-embedded sections and delayed closure.
  • AIM: The aim of the study was to determine the 5-year outcome of periocular basal cell carcinoma (BCC) managed by Mohs surgery using formalin-fixed, paraffin-embedded sections (Slow Mohs).
  • CONCLUSION: The low 5-year recurrence rate (0.58%) reported in this prospective series confirms the importance of margin-controlled removal of recurrent, poorly defined or critically sited BCCs, and illustrates that Slow Mohs is equivalent to standard Mohs.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery / methods. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esthetics. Female. Fixatives. Follow-Up Studies. Formaldehyde. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Paraffin Embedding. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19060015.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fixatives; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


65. Desai TD, Desai AD, Horowitz DC, Kartono F, Wahl T: The use of high-frequency ultrasound in the evaluation of superficial and nodular basal cell carcinomas. Dermatol Surg; 2007 Oct;33(10):1220-7; discussion 1226-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of high-frequency ultrasound in the evaluation of superficial and nodular basal cell carcinomas.
  • BACKGROUND: Frequencies of 20 MHz may be appropriate to visualize basal cell carcinomas (BCCs) including their tumor thickness and margins.
  • Morpheaform, recurrent BCCs, BCCs in areas difficult to scan, and BCCs with specific properties were excluded from this study.
  • It could be warranted if clinical or histologic diagnosis is uncertain.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903155.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Hassanpour SE, Kalantar-Hormozi A, Motamed S, Moosavizadeh SM, Shahverdiani R: Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients. Ann Plast Surg; 2006 Nov;57(5):509-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignant neoplasm.
  • There was no meaningful difference in safe resection margin for the first lesion between the 2 groups (P = 0.27); however, the number of recurrent lesions was significantly higher in group A (P = 0.003).
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Basal Cell / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / radiotherapy. Skin Neoplasms / surgery. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Plast Surg. 2007 May;58(5):589; author reply 589-90 [17452854.001]
  • (PMID = 17060730.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Dos Santos JN, Oliveira GQ, Gurgel CA, de Souza RO, Sales CB, de Aguiar Pires Valença Neto A, Ramos EA: Altered expression of cytokeratins in primary, recurrent and syndrome keratocystic odontogenic tumors. J Mol Histol; 2009 Aug;40(4):269-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of cytokeratins in primary, recurrent and syndrome keratocystic odontogenic tumors.
  • Keratocystic odontogenic tumor (KOT) is a benign cystic tumor that affects the jaw bones and may be associated with the nevoid basal cell carcinoma syndrome (NBCCS).
  • Twenty-five cases diagnosed as KOT, including primary and recurrent tumors and those associated with NBCCS, were submitted to immunohistochemical study for analysis of cytokeratins (CKs) 7, 8, 10, 13, 14, 18 and 19.
  • CK14 was expressed in all epithelial layers and in those areas where inflammation and subepithelial splits were present; this protein was preserved within the basal cells.
  • CK 18 was expressed mainly in the basal layer, whereas CK19 was expressed mainly on the intermediate and superficial layers.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Jaw Neoplasms / pathology. Keratins / biosynthesis. Neoplasm Recurrence, Local / pathology. Odontogenic Cysts / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19915949.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


68. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A, Delattre O, de Cremoux P, Aurias A: Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res; 2007;9(2):R24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.
  • INTRODUCTION: Typical medullary breast carcinoma (MBC) has recently been recognized to be part of the basal-like carcinoma spectrum, a feature in agreement with the high rate of TP53 mutations previously reported in MBCs.
  • The present study was therefore designed to identify phenotypic and genetic alterations that distinguish MBCs from basal-like carcinomas (BLC).
  • CONCLUSION: Our study has revealed that MBCs are part of the basal-like group and share common genomic alterations with BLCs, the most frequent being 1q and 8q gains and X losses; however, MBCs are a distinct entity within the basal-like spectrum, characterized by a higher rate of KRT 5/6 expression, a higher rate of gains and losses than BLCs, recurrent 10p, 9p and 16q gains, 4p losses, and 1q, 8p, 10p and 12p amplicons.
  • Our results thus contribute to a better understanding of the heterogeneity in basal-like breast tumors and provide potential diagnostic tools.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Neoplasms, Basal Cell / classification. Neoplasms, Basal Cell / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 2003 Apr-Jun;18(2):99-105 [12841678.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Int J Surg Pathol. 2003 Jul;11(3):153-8 [12894346.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):499-507 [14760071.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):830-5 [14871808.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5988-97 [15447982.001]
  • [Cites] Cancer. 1977 Oct;40(4):1365-85 [907958.001]
  • [Cites] Radiother Oncol. 1987 Sep;10(1):1-6 [3671767.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):641-3 [10203285.001]
  • [Cites] Nature. 1999 Sep 16;401(6750):297-300 [10499591.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8541-9 [15574760.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3413-22 [15381628.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):822-7 [15705879.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):333-9 [15958055.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1040-7 [15990007.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7612-21 [16140926.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2304-11 [16140006.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9727-34 [16266993.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1623-31 [16258515.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8577-84 [16361540.001]
  • [Cites] Histopathology. 2000 Aug;37(2):175-81 [10931242.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7110-7 [12460933.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] Histopathology. 2003 Apr;42(4):337-47 [12653945.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):628; author reply 628-9 [12697858.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):195-207 [16341153.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):121-32 [16473279.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):424-8 [16497871.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4636-44 [16651414.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):779-82 [16740027.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Histopathology. 2006 Jul;49(1):22-34 [16842243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • (PMID = 17417968.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1868916
  •  go-up   go-down


69. Lawrence CM, Haniffa M, Dahl MG: Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: 5-year follow-up data. Br J Dermatol; 2009 Mar;160(3):573-80
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: 5-year follow-up data.
  • BACKGROUND: Mohs surgery using a formalin-fixed tissue technique (slow Mohs) was used to treat 1090 basal cell carcinomas (BCCs) occurring in 1000 patients without Gorlin syndrome in a prospective, open nonrandomized trial of therapy carried out in a university dermatology department.
  • Within this group 21 tumour recurrences were identified, giving a 5-year cure rate of 97.2% for all patients, 97.8% for primary BCC and 95.3% for recurrent BCC.
  • There was a higher risk of recurrence for big (four of 78; 5%) and recurrent (nine of 193; 5%) BCCs compared with other indications for Mohs surgery.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Skin Neoplasms / surgery. Tissue Fixation / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Formaldehyde. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Pathology, Surgical / methods. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210500.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1HG84L3525 / Formaldehyde
  •  go-up   go-down


70. Ersu B, Tulunoglu I, Cengiz M: Periauricular mold brachytherapy. Brachytherapy; 2010 Jul-Sep;9(3):239-42
MedlinePlus Health Information. consumer health - Hearing Aids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We present a patient with recurrent basal cell carcinoma (BCCA) who was treated with custom-made mold brachytherapy.
  • METHODS AND MATERIALS: The patient was admitted to the hospital with the complaint of recurrent BCCA of the auditory canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19853538.001).
  • [ISSN] 1873-1449
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8024-51-9 / Inlay Casting Wax
  •  go-up   go-down


71. Kyrgidis A, Tzellos TG, Vahtsevanos K, Triaridis S: New concepts for basal cell carcinoma. Demographic, clinical, histological risk factors, and biomarkers. A systematic review of evidence regarding risk for tumor development, susceptibility for second primary and recurrence. J Surg Res; 2010 Mar;159(1):545-56
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New concepts for basal cell carcinoma. Demographic, clinical, histological risk factors, and biomarkers. A systematic review of evidence regarding risk for tumor development, susceptibility for second primary and recurrence.
  • Basal cell carcinoma (BCC) is the commonest cancer in Caucasians and its incidence is increasing.
  • In addition, not enough information exists on the prognostic value of existing demographic and clinical risk predictors for BCC regarding development of second primary or recurrent tumors.
  • Conclusively, we suggest that further studies aimed in investigating second primary or recurrent BCC are needed to provide better information on the predictive value of certain demographic, clinical and histological factors.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Basal Cell / etiology. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Second Primary / epidemiology. Skin Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19285687.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 86
  •  go-up   go-down


72. Kyrgidis A, Vahtsevanos K, Tzellos TG, Xirou P, Kitikidou K, Antoniades K, Zouboulis CC, Triaridis S: Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital. Eur J Dermatol; 2010 May-Jun;20(3):276-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital.
  • Basal cell carcinoma (BCC) accounts for nearly 25% of all cancers in the human body and for almost 75% of skin malignancies; approximately 85% of basal cell carcinomas develop in the head and neck region.
  • Limited demographic, clinical and histological predictors for second primary and/or recurrent BCC have been identified to date.
  • We included 1062 patients with a histologically confirmed diagnosis of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Hospitals, Special. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406722.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


73. Knopf A, Schneider J, Schipper J, Hoffmann TK, Bas M: [Sinonasal basaloid squamous cell carcinoma in biopsies of inverted papilloma]. HNO; 2008 Aug;56(8):808-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sinonasal basaloid squamous cell carcinoma in biopsies of inverted papilloma].
  • [Transliterated title] Das sinonasale basaloid-squamöse Karzinom in Biopsien eines invertierten Papilloms.
  • Basaloid squamous cell carcinoma (BSCC) is a rare tumor representing an aggressive variant of squamous cell carcinoma (SCC) and arising from a common precursor cell.
  • In any case, IP requires consequent endoscopic and, if necessary, radiological follow-up in order to detect recurrent disease or malignant transformation.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Squamous Cell / pathology. Papilloma, Inverted / pathology. Paranasal Sinus Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otolaryngol. 1996 Sep;116(5):762-5 [8908257.001]
  • [Cites] Laryngorhinootologie. 1999 Apr;78(4):189-93 [10407824.001]
  • [Cites] Indian J Pathol Microbiol. 2005 Jan;48(1):31-3 [16758784.001]
  • [Cites] Laryngoscope. 2003 Sep;113(9):1548-56 [12972932.001]
  • [Cites] J Laryngol Otol. 1992 Apr;106(4):370-1 [1613356.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2528-31 [2655872.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1689-93 [8625035.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Apr;262(4):263-8 [15258811.001]
  • [Cites] Cancer. 1982 Jul 1;50(1):154-8 [6805938.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):625-31 [2546458.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):333-7 [10623682.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2299-305 [7691390.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):841-54 [10091761.001]
  • [Cites] Laryngoscope. 2001 Aug;111(8):1401-5 [11568576.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1971 Apr;80(2):192-206 [4323842.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):537-42 [2364364.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 May;134(5):883-5 [16647553.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Laryngoscope. 1995 Mar;105(3 Pt 1):282-8 [7877417.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Nov;113(5):558-63 [7478645.001]
  • [Cites] HNO. 1994 Nov;42(11):670-6 [7843998.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Jul;113(1):49-55 [7603721.001]
  • [Cites] Cancer. 1997 May 15;79(10):1871-8 [9149011.001]
  • [Cites] Am J Surg Pathol. 1992 Oct;16(10):939-46 [1384369.001]
  • [Cites] Laryngoscope. 1989 Nov;99(11):1117-24 [2682100.001]
  • [Cites] Hum Pathol. 1984 May;15(5):460-8 [6327495.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1545-9 [1893355.001]
  • (PMID = 17876561.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC: Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis; 2010 Jun;85(6):318-24
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
  • We conducted a prospective, multicenter, phase 3, open-label study to assess long-term sustained clearance of superficial basal cell carcinomas (sBCCs) treated with imiquimod cream 5%.
  • Of 20 recurrent tumors, 74 (70%) occurred within the first 24 months of follow-up.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666194.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


75. Manié E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de Thé H, Stoppa-Lyonnet D, Stern MH: High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res; 2009 Jan 15;69(2):663-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
  • Breast tumors with a germ-line mutation of BRCA1 (BRCA1 tumors) and basal-like carcinoma (BLC) are associated with a high rate of TP53 mutation.
  • Because BRCA1 tumors frequently display a basal-like phenotype, this study was designed to determine whether TP53 mutations are correlated with the hereditary BRCA1 mutated status or the particular phenotype of these tumors.
  • In conclusion, TP53 mutation is highly recurrent in BLCs independently of BRCA1 status, but not a common feature of BRCA1 luminal tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Ductal, Breast / genetics. Genes, BRCA1. Genes, p53. Germ-Line Mutation. Mutation, Missense

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2009 Apr 1;69(7):3240
  • (PMID = 19147582.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Pereira PR, Odashiro AN, Rodrigues-Reyes AA, Correa ZM, de Souza Filho JP, Burnier MN Jr: Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol; 2005 Aug;32(7):496-501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological review of sebaceous carcinoma of the eyelid.
  • BACKGROUND: Sebaceous carcinoma of the eyelid can clinically mimic benign conditions, such as recurrent chalazion and inflammation and histopathologically squamous cell and basal cell carcinoma (BCC).
  • This retrospective study was undertaken as an attempt to improve the characterization and consequently the diagnosis of these tumors.
  • METHODS: Retrospective analysis was performed on eyelid specimens diagnosed as sebaceous carcinoma retrieved from Henry C.
  • Of these, 75% had features similar to squamous cell carcinoma (SqCC), some with dyskeratosis (30%) and 7% resembled BCC.
  • CONCLUSION: Sebaceous carcinoma presented as a poorly differentiated lesion in most cases of this series, which suggests a possibility of misdiagnosis because of its similarities to SqCC.
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Chalazion / diagnosis. Diagnosis, Differential. Humans. Retrospective Studies. Single-Blind Method. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008694.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


77. Huang CY, Feng CH, Hsiao YC, Chuang SS, Yang JY: Burn scar carcinoma. J Dermatolog Treat; 2010 Nov;21(6):350-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burn scar carcinoma.
  • INTRODUCTION: Since Jean-Nicolas Marjolin reported carcinoma arising in post-traumatic scars in 1828, the term 'Marjolin ulcer' has been applied to malignant changes in burn scars.
  • METHODS: From 1989 to 2008, there were 11 cases noted as burn scar carcinoma in Chang Gung Memorial Hospital.
  • Ten were reported as squamous cell carcinoma (SCC) and the one was verrucous carcinoma.
  • One patient received above-knee amputation and adjuvant therapy because recurrent verrucous carcinoma occurred 2 years later.
  • Most scar malignancies are SCC while other cell types are rarer.
  • CONCLUSION: The casual association between burn injuries and a later risk of basal cell carcinoma is questionable.
  • Owing to poor prognosis in advanced scar cancer, the best treatment for scar carcinoma is to prevent the scar from developing repeated ulceration by performing aggressive initial burn wound care: early grafting by surgeons and daily scar care with regular follow-up for patients.
  • [MeSH-major] Burns / complications. Carcinoma, Squamous Cell / surgery. Carcinoma, Verrucous / surgery. Cicatrix / complications. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438387.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, Movsas B, Ryu S: Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1047-53
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region.
  • METHODS AND MATERIALS: Patients with pathologically proven malignant lesions in the head-and-neck region were treated using single-dose SBRT (S-SBRT) or fractionated SBRT (F-SBRT).
  • There were three groups of patients: those with primary (n = 10), recurrent (n = 21), and metastatic tumors (n = 13).
  • The predominant histologic type was squamous cell carcinoma (n = 33).
  • Tumor control rates at 1 year were 83.3% and 60.6% in the primary and recurrent groups, respectively.
  • Median overall survival was 28.7, 6.7, and 5.6 months for the primary, recurrent, and metastatic groups, respectively.
  • CONCLUSIONS: The SBRT in single or fractionated doses offers a viable treatment option for selected patients with primary, recurrent, and metastatic head-and-neck cancers with functional preservation.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327895.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Shome D, Bell D, Esmaeli B: Eyelid carcinoma in patients with systemic lymphoma. J Ophthalmic Vis Res; 2010 Jan;5(1):38-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid carcinoma in patients with systemic lymphoma.
  • PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid carcinoma.
  • METHODS: In this non-comparative interventional case series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.
  • Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma.
  • The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases.
  • Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy.
  • Two patients had perineural invasion; one received adjuvant radiotherapy postoperatively but the other did not due to receiving systemic chemotherapy for recurrent NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9 [19033839.001]
  • [Cites] Am J Ophthalmol. 1986 Apr 15;101(4):480-2 [3515953.001]
  • [Cites] Arch Ophthalmol. 1980 Oct;98(10):1771-2 [7000053.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Acta Haematol. 1997;98(1):44-6 [9210914.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Dermatology. 2001;202(4):359-61 [11455161.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Curr Treat Options Oncol. 2004 Jun;5(3):215-23 [15115650.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]
  • [Cites] Histopathology. 2004 Aug;45(2):162-70 [15279635.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):985-8 [15313816.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):49-54 [15621780.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1051-5 [16019557.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):300-4 [16282752.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):231-6 [17034463.001]
  • (PMID = 22737325.001).
  • [ISSN] 2008-2010
  • [Journal-full-title] Journal of ophthalmic & vision research
  • [ISO-abbreviation] J Ophthalmic Vis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3380669
  • [Keywords] NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma
  •  go-up   go-down


80. Bhandarkar ND, Sims HS, David O: ProEx C stain analysis in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol; 2010 Feb;119(2):99-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ProEx C stain analysis in recurrent respiratory papillomatosis.
  • OBJECTIVES: We evaluated the presence and pattern of ProEx C stain, a marker for the proliferative capacity of cells, in laryngeal tissues, including benign, malignant, and recurrent respiratory papilloma (RRP) specimens, and compared it to hematoxylin and eosin staining for the presence of dysplasia.
  • RESULTS: A total of 26 specimens (9 benign, 7 malignant, 10 RRP) representing 21 patients were stained.
  • The malignant specimens were either well or moderately differentiated squamous cell carcinoma, and they stained strongly and diffusely.
  • In benign and RRP specimens, the basal layer typically stained positive.
  • [MeSH-major] Antigens, Neoplasm / analysis. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Papilloma / chemistry. Respiratory Tract Neoplasms / chemistry
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cell Proliferation. Diagnosis, Differential. Humans. Immunohistochemistry. Isoenzymes. Minichromosome Maintenance Complex Component 2. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20336920.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Isoenzymes; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


81. Narayana A, Cohen GN, Zaider M, Chan K, Lee N, Wong RJ, Boyle J, Shaha A, Kraus D, Shah J, Zelefsky MJ: High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results. Brachytherapy; 2007 Apr-Jun;6(2):157-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results.
  • PURPOSE: Although high-dose-rate brachytherapy (HDRBT) offers significant advantages over low dose rate brachytherapy, there are scant data on improved local control (LC) and treatment-related complications in patients with recurrent head and neck (H&N) cancers.
  • We report our preliminary results in patients with recurrent H&N cancers treated with interstitial HDRBT.
  • METHODS AND MATERIALS: Thirty patients with recurrent H&N cancers were treated with HDRBT between September 2003 and October 2005.
  • CONCLUSION: The preliminary results of HDRBT indicate an acceptable LC and morbidity in recurrent H&N cancers.
  • Based on these encouraging results, prospective clinical trials are warranted using HDRBT in recurrent H&N cancers to decrease late toxicity.
  • [MeSH-major] Brachytherapy. Head and Neck Neoplasms / radiotherapy. Hemibody Irradiation. Neoplasm Recurrence, Local
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Follow-Up Studies. Humans. Male. Melanoma / radiotherapy. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Retrospective Studies. Sarcoma / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden / radiation effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434110.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Veness MJ: High-risk cutaneous squamous cell carcinoma of the head and neck. J Biomed Biotechnol; 2007;2007(3):80572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-risk cutaneous squamous cell carcinoma of the head and neck.
  • Nonmelanoma skin cancers (squamous cell and basal cell carcinomas) occur at an epidemic rate in many countries with the worldwide incidence increasing.
  • The sun-exposed head and neck are the most frequent sites for these cancers to arise and in most patients diagnosed with a cutaneous squamous cell carcinoma, local treatment is usually curative.
  • However, a subset is diagnosed with a high-risk cutaneous squamous cell carcinoma.
  • High-risk factors include size (>2 cm), thickness/depth of invasion (>4 mm), recurrent lesions, the presence of perineural invasion, location near the parotid gland, and immunosuppression.
  • Despite treatment, many patients developing metastatic cutaneous squamous cell carcinoma experience mortality and morbidity usually as a consequence of uncontrolled metastatic nodal disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2005 Sep;115(9):1561-7 [16148695.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 May;124(5):582-7 [9604987.001]
  • [Cites] Dermatol Surg. 2000 Mar;26(3):289-92 [10759812.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):18-25 [11841362.001]
  • [Cites] Dermatol Surg. 2002 Mar;28(3):268-73 [11896781.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 May;128(5):521-6 [12003582.001]
  • [Cites] Int J Oral Maxillofac Surg. 2002 Apr;31(2):154-7 [12102412.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):301-6 [12622621.001]
  • [Cites] Plast Reconstr Surg. 2003 Jul;112(1):57-63 [12832877.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1027-33 [14648861.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):92-8 [14662421.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):223-7 [14693248.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):651-5 [15061850.001]
  • [Cites] Semin Cutan Med Surg. 2004 Sep;23(3):167-73 [15584682.001]
  • [Cites] J Am Acad Dermatol. 2005 Jan;52(1):101-8 [15627087.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):551-5 [16027274.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] Australas Radiol. 2005 Oct;49(5):365-76 [16174174.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):1067-71 [16310071.001]
  • [Cites] Head Neck. 2006 Mar;28(3):244-8 [16395715.001]
  • [Cites] Med J Aust. 2006 Jan 2;184(1):6-10 [16398622.001]
  • [Cites] J Cutan Pathol. 2006 Apr;33(4):261-79 [16630176.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2389-96 [16649220.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):902-9 [16788750.001]
  • [Cites] Dermatol Surg. 2006 Sep;32(9):1163-70 [16970698.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):624-7 [2239827.001]
  • [Cites] Head Neck. 1989 May-Jun;11(3):264-8 [2722504.001]
  • [Cites] Hum Pathol. 1986 Apr;17(4):346-54 [3957335.001]
  • [Cites] Head Neck Surg. 1980 May-Jun;2(5):361-5 [7364589.001]
  • [Cites] Dermatology. 1994;189(1):52-4 [8003787.001]
  • [Cites] J Am Acad Dermatol. 1993 Apr;28(4):628-31 [8463466.001]
  • [Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):156-8 [8583845.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1758-64 [10223570.001]
  • (PMID = 17541471.001).
  • [ISSN] 1110-7243
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1874675
  •  go-up   go-down


83. Mátrai Z, Plotár V, Liszkay G, Fejos Z, Vámosi A, Dubóczky Z, Rényi Vámos F, Vámosi Nagy I, Köves I, Bartal A, Schmidt E, Tóth L: [Recurrent acral lentigous melanoma successfully treated with Mohs' micrographic surgery. Case report and review of the literature]. Orv Hetil; 2009 Jun 7;150(23):1071-82
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent acral lentigous melanoma successfully treated with Mohs' micrographic surgery. Case report and review of the literature].
  • Mohs' micrographic surgery is the method of choice for removal of large, recurrent or incompletely excised skin cancers or for tumors located in functional and aesthetic relevant anatomic regions.
  • The authors present a case of a 75-year-old man with a second time recurrent plantar invasive malignant melanoma successfully treated with Mohs' micrographic surgery technique and an immediate reconstruction using split-thickness skin graft.
  • [MeSH-major] Melanoma / pathology. Melanoma / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Frozen Sections. Humans. Male. Skin Transplantation. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470423.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 46
  •  go-up   go-down


84. Yang QS, Gu JL, Du LQ, Jia LL, Qin LL, Wang Y, Fan FY: ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines. J Radiat Res; 2008 Jul;49(4):399-407
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines.
  • To investigate the effects of Ku80 depletion on cell growth and sensitization to gamma-radiation and MMC-induced apoptosis in esophageal squamous cell carcinoma lines.
  • Six human carcinoma cell lines (LNcaP, K562, MDA-MB-231, MCF-7, EC9706, and K150) and normal HEK293 cell line were examined for basal levels of Ku80 protein by western blotting analysis.
  • Cell proliferation was determined with MTT assay and colony formation assay and tumorigenicity in a xenograft model in vitro and in vivo.
  • The cell cycle distribution was determined by Flow cytometry.
  • Ku80 showed higher basal levels in six carcinoma cell lines than in HEK293.
  • Hence Ku80 may serve as a promising therapeutic target, particularly for recurrent esophageal tumors.
  • [MeSH-major] Antigens, Nuclear / metabolism. Apoptosis / drug effects. Apoptosis / radiation effects. Carcinoma, Squamous Cell / metabolism. Cell Proliferation / drug effects. Cell Proliferation / radiation effects. DNA-Binding Proteins / metabolism. Esophageal Neoplasms / metabolism. Mitomycin / administration & dosage
  • [MeSH-minor] Cell Line, Tumor. Gamma Rays. Gene Silencing. Humans. RNA, Small Interfering / genetics. Radiation Tolerance / drug effects. Radiation Tolerance / radiation effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403903.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; 0 / RNA, Small Interfering; 50SG953SK6 / Mitomycin
  •  go-up   go-down


85. Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R: Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Feb;52(2):295-300
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is reported to have a high rate of recurrence with standard wide local excision.
  • In 31.8% of cases it was a recurrent tumor.
  • In 32.5% of cases the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.
  • Perineural invasion was recorded in 17.5% of cases; most of them (85.7%) were previously recurrent tumors.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Australia / epidemiology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Child. Databases, Factual. Diagnostic Errors. Female. Follow-Up Studies. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692477.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


86. Yang Z, Sui Y, Xiong S, Liour SS, Phillips AC, Ko L: Switched alternative splicing of oncogene CoAA during embryonal carcinoma stem cell differentiation. Nucleic Acids Res; 2007;35(6):1919-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Switched alternative splicing of oncogene CoAA during embryonal carcinoma stem cell differentiation.
  • During retinoic-acid-induced P19 stem cell differentiation, the expression of CoAA undergoes a rapid switch to its dominant negative splice variant CoAM in the cavity of the embryoid body.
  • Using a CoAA minigene cassette, we find that the switched alternative splicing of CoAA and CoAM is regulated by the cis-regulating sequence upstream of the CoAA basal promoter.
  • We have previously shown that the CoAA gene is amplified in human cancers with a recurrent loss of this cis-regulating sequence.
  • These results together suggest that the upstream regulatory sequence contributes to alternative splicing of the CoAA gene during stem cell differentiation, and its selective loss in human cancers potentially deregulates CoAA alternative splicing and alters stem cell differentiation.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Carcinoma, Embryonal / genetics. Carcinoma, Embryonal / metabolism. Cell Differentiation. Cell Line, Tumor. DNA-Binding Proteins / biosynthesis. Gene Expression Regulation, Developmental. High Mobility Group Proteins / biosynthesis. Mice. Molecular Sequence Data. Nuclear Matrix-Associated Proteins / metabolism. RNA-Binding Proteins / metabolism. Regulatory Elements, Transcriptional. SOXD Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Oct 11;298(5592):416-9 [12376702.001]
  • [Cites] RNA. 2002 Sep;8(9):1102-11 [12358429.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1359-69 [12628928.001]
  • [Cites] Cardiovasc Res. 2003 May 1;58(2):292-302 [12757864.001]
  • [Cites] J Cell Biol. 1982 Aug;94(2):253-62 [7107698.001]
  • [Cites] Annu Rev Genet. 1989;23:527-77 [2694943.001]
  • [Cites] Nature. 1990 Mar 29;344(6265):435-9 [1690859.001]
  • [Cites] Mol Cell Biol. 1993 Nov;13(11):6742-51 [7692231.001]
  • [Cites] Trends Biochem Sci. 1995 Jun;20(6):235-40 [7543225.001]
  • [Cites] Development. 1999 Feb;126(3):535-46 [9876182.001]
  • [Cites] Cell. 1999 Feb 5;96(3):307-10 [10025395.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1409-20 [10037800.001]
  • [Cites] Mol Genet Metab. 1999 Jul;67(3):183-93 [10381326.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):363-71 [10395553.001]
  • [Cites] Cell Biol Int. 2004;28(11):791-9 [15563401.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6261-3 [15591240.001]
  • [Cites] J Cell Biochem. 2005 Feb 1;94(2):257-65 [15546139.001]
  • [Cites] Trends Mol Med. 2005 Jan;11(1):5-9 [15649816.001]
  • [Cites] Gene. 2005 Jan 3;344:1-20 [15656968.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):342-57 [15648050.001]
  • [Cites] FEBS J. 2005 May;272(9):2118-31 [15853797.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):262-8 [15901495.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21022-8 [15793308.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):386-98 [15956978.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5307-16 [15964789.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6734-46 [16024807.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):6912-20 [16055705.001]
  • [Cites] Trends Biochem Sci. 2005 Sep;30(9):515-21 [16023350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14290-5 [16183747.001]
  • [Cites] Glia. 2006 Jan 1;53(1):43-56 [16158417.001]
  • [Cites] RNA. 2006 Jan;12(1):111-21 [16373496.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):347-51 [16479168.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):756-63 [16767080.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):822-35 [16878147.001]
  • [Cites] Gene. 1999 Nov 1;239(2):341-9 [10548736.001]
  • [Cites] Cell. 2003 May 30;113(5):551-2 [12787492.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Sep;67(3):343-59, table of contents [12966139.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42750-60 [12917399.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):442-53 [14673176.001]
  • [Cites] FEBS Lett. 2004 Feb 27;560(1-3):192-8 [14988021.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1834-44 [15057274.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1782-91 [15057275.001]
  • [Cites] RNA. 2004 Oct;10(10):1489-98 [15383674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6212-7 [10823961.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1285-96 [11158314.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33375-83 [11443112.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):92-7 [11689953.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):13-9 [11753382.001]
  • [Cites] Curr Biol. 2002 Jan 8;12(1):1-11 [11790298.001]
  • [Cites] Curr Biol. 2002 Jan 8;12(1):13-25 [11790299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1146-51 [11818535.001]
  • [Cites] Cell. 2002 Feb 22;108(4):501-12 [11909521.001]
  • [Cites] Nat Rev Genet. 2002 May;3(5):370-9 [11988762.001]
  • [Cites] Curr Opin Genet Dev. 2002 Aug;12(4):441-6 [12100890.001]
  • [Cites] Dev Cell. 2002 Aug;3(2):167-70 [12194848.001]
  • [Cites] FEBS Lett. 2002 Nov 6;531(2):109-14 [12417296.001]
  • (PMID = 17337438.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ294957
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CoAA protein, mouse; 0 / DNA-Binding Proteins; 0 / High Mobility Group Proteins; 0 / Nuclear Matrix-Associated Proteins; 0 / Oncogene Proteins; 0 / PTB-associated splicing factor; 0 / RNA-Binding Proteins; 0 / SOXD Transcription Factors; 0 / Sox6 protein, mouse; 0 / Transcription Factors; 0 / p54nrb protein, mouse
  • [Other-IDs] NLM/ PMC1874587
  •  go-up   go-down


87. Tan PY, Ek E, Su S, Giorlando F, Dieu T: Incomplete excision of squamous cell carcinoma of the skin: a prospective observational study. Plast Reconstr Surg; 2007 Sep 15;120(4):910-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of squamous cell carcinoma of the skin: a prospective observational study.
  • BACKGROUND: Squamous cell carcinoma is the second most common cancer of the skin.
  • It behaves differently from basal cell carcinoma.
  • Few large-scale studies have identified risk factors for incomplete excision of cutaneous squamous cell carcinoma.
  • METHODS: A total of 517 histopathologically confirmed squamous cell carcinomas were excised from January of 2001 to December of 2002 at the Peter MacCallum Cancer Institute.
  • Age (p = 0.61), sex (p = 0.075), tumor size (p = 0.521), surgeon's experience (p = 0.092), and recurrent lesions (p = 0.408) were not statistically significant risk factors.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805118.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Varga E, Kiss M, Szabó K, Kemény L: Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas. Br J Dermatol; 2009 Oct;161(4):930-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive tumour for which an increasing incidence has been reported.
  • A new human polyomavirus, Merkel cell polyomavirus (MCV), was recently isolated from these tumours by applying digital transcriptome subtraction methodology.
  • METHODS: Nine primary or recurrent MCCs from seven patients were examined; 29 other tumours (squamous cell, basal cell and basosquamous carcinomas and malignant melanomas) were examined for comparative purposes.
  • [MeSH-major] Antigens, Viral, Tumor / genetics. Capsid Proteins / genetics. Carcinoma, Merkel Cell / virology. Polyomaviridae / genetics. Polyomavirus Infections / virology. Skin Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438857.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / Capsid Proteins
  •  go-up   go-down


89. Raspagliesi F, Fontanelli R, Rossi G, Ditto A, Solima E, Hanozet F, Kusamura S: Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study. Gynecol Oncol; 2006 Nov;103(2):581-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study.
  • Photodynamic therapy (PDT) using 5-aminolevulinic acid (5 ALA) is an effective treatment for some conditions such as Bowen's disease, subsets of basal cell carcinomas and vulvar carcinoma.
  • This paper outlines a pilot study designed to test the feasibility of using MAL-PDT in the treatment of recurrent vulvar Paget's disease.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Paget Disease, Extramammary / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793128.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / delta-aminolevulinic acid methyl ester; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


90. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basosquamous carcinoma: treatment with Mohs micrographic surgery. Cancer; 2005 Jul 1;104(1):170-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Basosquamous carcinoma (BSC) is a rare tumor defined as a basal cell carcinoma (BCC) differentiating into squamous cell carcinoma (SCC).
  • Recurrent tumors occurred in 47.8% of patients.
  • Most of these (69.0%) were previously recurrent tumors.
  • [MeSH-major] Carcinoma, Basosquamous / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods
  • [MeSH-minor] Adult. Aged. Arm. Female. Follow-Up Studies. Humans. Leg. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929123.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


91. Moskalik K, Kozlow A, Demin E, Boiko E: Powerful neodymium laser radiation for the treatment of facial carcinoma: 5 year follow-up data. Eur J Dermatol; 2010 Nov-Dec;20(6):738-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Powerful neodymium laser radiation for the treatment of facial carcinoma: 5 year follow-up data.
  • A retrospective non-comparative follow-up study was performed to evaluate the curative efficacy of powerful neodymium laser radiation (λ = 1,060 nm) for the treatment of 2,837 patients with 3,001 histologically confirmed facial skin carcinoma lesions of stages T1-2N0M0: 2,743 primary basal cell carcinomas (BCC), 172 recurrent limited basal cell carcinomas (RLBCC), and 86 primary squamous cells carcinomas (SCC).
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Laser Therapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neodymium. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21056940.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 2I87U3734A / Neodymium
  •  go-up   go-down


92. Desai RS, Donnelly HB: Repair of a glabellar and inferior forehead defect. Dermatol Surg; 2006 Jan;32(1):112-4
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This 44-year-old healthy white male was referred to our office for the treatment of a recurrent basal cell carcinoma clinically involving the left inferior forehead extending down to the left glabellar region of the face.
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Humans. Male. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2007 Jan;33(1):126-7 [17214696.001]
  • (PMID = 16393611.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Jun;52(6):997-1002
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery.
  • BACKGROUND: Bowen's disease (BD), also known as squamous intraepidermal carcinoma, is a malignant skin tumor with a potential to progress to invasive carcinoma.
  • In 50.7% of cases it was a recurrent tumor.
  • In 20% the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928618.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


94. Garvey C, Turner H: The use of a custom earmold to prevent recurrent external auditory canal stenosis. J Am Acad Audiol; 2008 Mar;19(3):233-6
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of a custom earmold to prevent recurrent external auditory canal stenosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Constriction, Pathologic / prevention & control. Ear, External / pathology. Postoperative Complications. Stents
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672651.001).
  • [ISSN] 1050-0545
  • [Journal-full-title] Journal of the American Academy of Audiology
  • [ISO-abbreviation] J Am Acad Audiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


95. Lustgarten L, Abadi JR, Sancevic R, Meneses P, Perez Morrel A, Lugo J: Use of a protein-based tissue adhesive as an aid for the surgical reconstruction of advanced and recurrent skin cancer tumors to the head and neck region: a technical report. Surg Neurol; 2007 Jul;68(1):53-9; discussion 59
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a protein-based tissue adhesive as an aid for the surgical reconstruction of advanced and recurrent skin cancer tumors to the head and neck region: a technical report.
  • Pathology included squamous (7) and basal (3) cell carcinoma and malignant schwannoma (1).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / surgery. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Craniotomy. Dura Mater / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neurilemmoma / surgery. Nose / surgery. Orbit / surgery. Postoperative Complications / mortality

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586223.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bio-glue; 0 / Proteins; 0 / Tissue Adhesives
  •  go-up   go-down


96. Pan S, Li TJ: PTCH1 mutations in odontogenic keratocysts: are they related to epithelial cell proliferation? Oral Oncol; 2009 Oct;45(10):861-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTCH1 mutations in odontogenic keratocysts: are they related to epithelial cell proliferation?
  • Mutations in PTCH1 gene are responsible for majority of nevoid basal cell carcinoma syndrome (NBCCS) as well as for some related sporadic neoplasms.
  • Mutations of PTCH1 would lead to constitutive activation of Sonic hedgehog (SHH) signaling pathway and result in aberrant cell proliferation.
  • The epithelial cell proliferation as assessed by Ki67 labeling was studied in a total cohort of 62 OKCs (42 sporadic and 20 syndromic cases) with known PTCH1 status.
  • These results suggest that PTCH1 mutations, particularly those causing protein truncations, are associated with a subgroup of OKCs showing increased proliferative activity and thus may relate to a phenotype of higher recurrent tendency.
  • [MeSH-major] Basal Cell Nevus Syndrome / genetics. Odontogenic Cysts / genetics. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. DNA Mutational Analysis. Epithelial Cells / metabolism. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19362041.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


97. González Moles MA, Mosqueda-Taylor A, Esteban F, Gil-Montoya JA, Díaz-Franco MA, Delgado M, Muñoz M: Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol; 2008 Dec;44(12):1127-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours.
  • The expression of substance P (SP) and its NK-1 receptor (NK-1R) in keratocystic odontogenic tumours (KOTs) was studied to determine whether the intrinsic growth potential of these lesions is related to a cell proliferation stimulus mediated by the SP/NK-1R complex.
  • A total of 65 tissue samples of solitary non-recurrent KOTs, solitary recurrent KOTs, KOTs associated with nevoid basal cell carcinoma syndrome (NBCCS) and KOTs with chondroid wall were studied by immunohistochemistry, using anti-SP, anti-NK-1R and anti-Ki-67 monoclonal antibodies.
  • KOTs associated with NBCCS showed a significantly higher SP expression in all tissues and cell compartments compared with other KOT types.
  • This first published report on SP and NK-1R expressions in KOTs demonstrates that actions of the SP/NK-1R complex may constitute a mechanism to stimulate epithelial cell proliferation in KOT.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Neoplasm Proteins / metabolism. Odontogenic Tumors / metabolism. Receptors, Neurokinin-1 / metabolism. Substance P / metabolism
  • [MeSH-minor] Adult. Cell Proliferation / drug effects. Epithelial Cells / metabolism. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486533.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Neurokinin-1; 33507-63-0 / Substance P
  •  go-up   go-down


98. Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K: Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res; 2006 Aug;16(4):211-6
MedlinePlus Health Information. consumer health - Hypoglycemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia.
  • In some patients with non-islet-cell tumor hypoglycemia (NICTH), a high molecular weight form of IGF-II (big IGF-II) derived from tumors is present in the circulation and might be associated with recurrent hypoglycemia.
  • Hepatocellular carcinoma and gastric carcinoma were the most common causes of NICTH.
  • Basal immunoreactive insulin (IRI) levels were less than 3 microU/dl in 79% of the patients.
  • These data suggested that hypoinsulinemic hypoglycemia associated with the presence of a large tumor supports the diagnosis of IGF-II producing NICTH.
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / secretion. Adult. Aged. Aged, 80 and over. Blood Glucose / analysis. Breast Neoplasms / secretion. Carcinoma, Hepatocellular / secretion. Carcinoma, Renal Cell / secretion. Child. Female. Fibrosarcoma / secretion. Gastrointestinal Stromal Tumors / secretion. Humans. Insulin-Like Growth Factor I / analysis. Insulin-Like Growth Factor II. Leiomyosarcoma / secretion. Liver Neoplasms / secretion. Male. Middle Aged. Pancreatic Neoplasms / secretion. Pheochromocytoma / secretion. Prostatic Neoplasms / secretion. Retrospective Studies. Stomach Neoplasms / secretion

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860583.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / IGF2 protein, human; 0 / Proteins; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


99. Kudrina MI, Vinogradova NN, Kolen'ko NG, Zaev SN: [Skin tumours and primary multiple malignant neoplasms]. Klin Med (Mosk); 2009;87(2):60-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin tumours and primary multiple malignant neoplasms].
  • The structure of recurrent malignant neoplasms was analysed in a group of patients followed up on a permanent basis after the treatment for skin cancer.
  • Observation of 2801 patients with primary basal and squamous cell skin cancer during 32 years (1975-2006) revealed 740 recurrent malignant neoplasms largely affecting skin, gastrointestinal tract, lungs, mammary and prostate glands.
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Incidence. Male. Mass Screening / methods. Retrospective Studies. Russia / epidemiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348305.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


100. Terziqi H, Tarpila E: Reconstruction of large defect of lower lip and commissure using Karapandzic flap: case report. Niger J Med; 2009 Apr-Jun;18(2):222-3
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present an 18-years-old boy with XP and recurrent basal and squamous cell carcinoma of lower lip.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / surgery. Reconstructive Surgical Procedures. Surgical Flaps. Xeroderma Pigmentosum / pathology
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630336.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down






Advertisement